首页> 外文期刊>World Journal of Gastroenterology >Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis
【24h】

Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis

机译:遗传性血色素沉着中含有-3 基因I148M多态性,脂肪变性和肝损伤的patatin样磷脂酶结构域

获取原文

摘要

AIM: To investigate whether the patatin-like phospholipase domain containing-3 gene (PNPLA3) I148M polymorphism is associated with steatosis, fibrosis stage, and cirrhosis in hereditary hemochromatosis (HH). METHODS: We studied 174 consecutive unrelated homozygous for the C282Y HFE mutation of HH (C282Y+/+ HH) patients from Northern Italy, for whom the presence of cirrhosis could be determined based on histological or clinical criteria, without excessive alcohol intake (n = 100) or ultrasound (n = 23). The PNPLA3 rs738409 single nucleotide polymorphism, encoding for the p.148M protein variant, was genotyped by a Taqman assay (assay on demand, Applied Biosystems). The association of the PNPLA3 I148M protein variant (p.I148M) with steatosis, fibrosis stage, and cirrhosis was evaluated by logistic regression analysis. RESULTS: PNPLA3 genotype was not associated with metabolic parameters, including body mass index (BMI), the presence of diabetes, and lipid levels, but the presence of the p.148M variant at risk was independently associated with steatosis [odds ratio (OR) 1.84 per p.148M allele, 95% confidence interval (CI): 1.05-3.31; P = 0.037], independently of BMI and alanine aminotransaminase (ALT) levels. The p.148M variant was also associated with higher aspartate aminotransferase (P = 0.0014) and ALT levels (P = 0.017) at diagnosis, independently of BMI and the severity of iron overload. In patients with liver biopsy, the 148M variant was independently associated with the severity (stage) of fibrosis (estimated coefficient 0.56 ± 0.27, P = 0.041). In the overall series of patients, the p.148M variant was associated with cirrhosis in lean (P = 0.049), but not in overweight patients (P = not significant). At logistic regression analysis, cirrhosis was associated with BMI ≥ 25 (OR 1.82, 95% CI: 1.02-3.55), ferritin > 1000 ng/mL at diagnosis (OR 19.3, 95% CI: 5.3-125), and with the G allele in patients with BMI CONCLUSION: The PNPLA3 I148M polymorphism may represent a permissive factor for fibrosis progression in patients with C282Y+/+ HH.
机译:目的:研究含patatin样磷脂酶结构域的3基因(PNPLA3)I148M多态性是否与遗传性血色素沉着症(HH)的脂肪变性,纤维化分期和肝硬化有关。方法:我们研究了来自意大利北部HH(C282Y + / + HH)患者的C282Y HFE突变的174个连续无关纯合子,可以根据组织学或临床标准确定其是否存在肝硬化,而无需过量饮酒(n = 100 )或超声检查(n = 23)。通过Taqman测定(按需测定,Applied Biosystems)对PNPLA3 rs738409单核苷酸多态性(编码p.148M蛋白变体)进行基因分型。通过逻辑回归分析评估了PNPLA3 I148M蛋白变体(p.I148M)与脂肪变性,纤维化分期和肝硬化的关系。结果:PNPLA3基因型与代谢参数(包括体重指数(BMI),糖尿病和血脂水平)无关,但存在危险的p.148M变体与脂肪变性[几率(OR)]独立相关每个p.148M等位基因1.84,95%置信区间(CI):1.05-3.31; P = 0.037],与BMI和丙氨酸氨基转氨酶(ALT)水平无关。 p.148M变体在诊断时还与更高的天冬氨酸转氨酶(P = 0.0014)和ALT水平(P = 0.017)相关,与BMI和铁超负荷的严重程度无关。在肝活检患者中,148M变异与纤维化的严重程度(阶段)独立相关(估计系数0.56±0.27,P = 0.041)。在整个患者系列中,p.148M变体与瘦型肝硬化相关(P = 0.049),但与超重患者无肝硬化相关性(P =不显着)。在logistic回归分析中,肝硬化与BMI≥25(OR 1.82,95%CI:1.02-3.55),铁蛋白> 1000 ng / mL在诊断时(OR 19.3,95%CI:5.3-125)以及G有关。结论:PNPLA3 I148M基因多态性可能代表了C282Y + / + HH患者纤维化进展的允许因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号